The U.S. Centers for Disease Control and Prevention (CDC) has revised its guidance on COVID-19 vaccines for children, stating that vaccination for healthy individuals aged 6 months to 17 years should follow a “shared clinical decision-making” process. This means that shots are still available, but only if parents and doctors agree it's necessary based on individual circumstances.
The move marks a shift from earlier CDC guidance, which broadly recommended updated COVID-19 vaccines for everyone six months and older. The updated schedule, published Thursday, outlines that if parents want their child vaccinated, they may proceed based on a healthcare provider’s judgment and the family’s preference.
Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic, claimed earlier in the week that COVID vaccines for healthy children and pregnant women had been removed from the CDC’s immunization schedule. However, a Department of Health and Human Services spokesperson said there is no contradiction, as the CDC’s updated guidance no longer promotes universal vaccination for healthy children but still allows it case-by-case.
Medical experts criticized Kennedy’s unilateral announcement, saying it bypassed the CDC’s usual advisory process. The Infectious Diseases Society of America warned the change may limit access and insurance coverage, especially for vulnerable children. They emphasized that COVID-19 can cause serious illness in children, including long COVID symptoms that may impact development.
According to CDC data, nearly 1,900 children under 18 have died from COVID-19 in the U.S. as of 2023. Vaccine makers Pfizer, Moderna, and Novavax have not commented on the development.
The FDA also recently announced it would require new clinical trials for annual COVID boosters in healthy individuals under 65, reinforcing a more limited use strategy moving forward.


Australia Launches Public Hearings on Bondi Beach Shooting and Rising Antisemitism
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
US House Advances $70 Billion Immigration Enforcement Budget Plan
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Federal and State Authorities Conduct Widespread Fraud Raids Across Minnesota
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case
New York Moves to Ban Masked Law Enforcement During Immigration Operations
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship
U.S. Sanctions Former DR Congo President Joseph Kabila Over Rebel Support 



